webleads-tracker

Transparency

juillet, 2018

  • 4 juillet

    Open Payments Data 2017: Significant Drop in Number of Payments

    Pharma Compliance Info Open Payments Data 2017: Significant Drop in Number of Payments US Sunshine Act

    On Friday, June 29, 2018 the Centers for Medicare & Medicaid Services (“CMS”) released the 2017 Open Payments Data, which covers transactions data collected from January 1, 2016 through December 31, 2016. The total dollar amount of payments totaled $8.4 billion (General Payments: $2.82 billion; Research Payments: $4.66 billion; the total records published totaled 11.54 million. The 2017 Open Payments Data shows a 4.7% drop in the total amount of payments from applicable manufacturers and group purchasing organizations (“GPO”) and a 6.9% drop in the total number of payments. To read the article by Thomas Sullivan

  • 4 juillet

    The Patient Advocacy Groups that Accept the Most Big Pharma Money

    Pharma Compliance Info The Patient Advocacy Groups that Accept the Most Big Pharma Money US Sunshine Act

    Eight out of ten patient advocacy groups accept money from drug and medical device companies. Pharmaceutical donations make up more than half of the yearly income of some patient advocacy groups. Are these good natured corporate donations, or just another way that Big Pharma exerts their influence beyond corporate walls? That question isn’t an easy one to answer. But the first step in understanding how large of a role pharmaceutical companies play in organizations like the American Diabetes Association or the American Heart Association is to follow the money. Pharmaceutical donations make up more than half of the yearly income …

  • 4 juillet

    Sunshine Act | The Facts About 2017 Open Payments Data

    Pharma Compliance Info Sunshine Act | The Facts About 2017 Open Payments Data US Sunshine Act

    Use the Search Tool to conduct your own specific search

  • 2 juillet

    De la loi DMOS à la loi Anti-Cadeaux

    Pharma Compliance Info De la loi DMOS à la loi Anti-Cadeaux Loi Bertrand

    Bien que la nouvelle loi Anti-cadeaux n’ait pas encore vu le jour, il n’est pas inutile de rappeler le contexte de la loi DMOS de 1993 et d’en tirer les conséquences pratiques. Par ailleurs, il est possible de discerner dores et déjà quelques changements majeurs introduits par la nouvelle loi. Éclaircissements avec Stéphanie Roucou, directrice de La Fonderie Ressources et Thierry Souchon, Pharmacien Responsable Allergan France. Pour lire l’article de Stéphanie Roucou et Thierre Souchon

juin, 2018

  • 12 juin

    Senator McCaskill Introduces: The Patient Advocacy Transparency Act of 2018

    Pharma Compliance Info Senator McCaskill Introduces: The Patient Advocacy Transparency Act of 2018 US Sunshine Act

    As a follow-up to Senator Claire McCaskill’s long running opioid investigation and report titled: Fueling an Epidemic: Exposing the Financial Ties Between Opioid Manufacturers and Third Party Advocacy Groups, the senator released the Patient Advocacy Transparency Act of 2018.  The proposed legislation, if adopted, would expand Open Payment reporting to include television programs, websites, and payments to patient advocacy organizations, professional societies, clinical trial organizations, and Continuing Medica Education (CME) providers. This legislation amends the Physician Payment Sunshine Act to: Broaden the reporting definition of “grants” to include various types of educational grants and “capacity building grants”; Also expands reporting for: fundraising …

  • 12 juin

    AstraZeneca to Reveal HCP Payments Worldwide

    Pharma Compliance Info AstraZeneca to Reveal HCP Payments Worldwide Global

    Pharmas’ payments to doctors raise concerns about prescription bias and have triggered bribery investigations, too. So, to win patients’ trust, transparency matters. And now, AstraZeneca is going beyond its Big Pharma fellows to disclose all its doc payments, even in regions where it’s not required. CEO Pascal Soriot told investors at its annual meeting that his company plans to disclose payments in all countries where it has commercial activities, according to The Times. Several countries, including the U.S., require those disclosures under local regulations. “There was no reason for us not to disclose,” said Soriot, as quoted by The Times of London. “It’s only a …

X